{
    "Symbol": "MRNA",
    "AssetType": "Common Stock",
    "Name": "Moderna Inc",
    "Description": "Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.",
    "CIK": "1682852",
    "Exchange": "NASDAQ",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)",
    "Address": "200 TECHNOLOGY SQUARE, CAMBRIDGE, MA, US",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2024-03-31",
    "MarketCapitalization": "33281006000",
    "EBITDA": "-4107000064",
    "PERatio": "None",
    "PEGRatio": "0",
    "BookValue": "30.5",
    "DividendPerShare": "None",
    "DividendYield": "None",
    "EPS": "-15.6",
    "RevenuePerShareTTM": "13.22",
    "ProfitMargin": "-1.162",
    "OperatingMarginTTM": "-5.66",
    "ReturnOnAssetsTTM": "-0.154",
    "ReturnOnEquityTTM": "-0.409",
    "RevenueTTM": "5050000000",
    "GrossProfitTTM": "10552000000",
    "DilutedEPSTTM": "-15.6",
    "QuarterlyEarningsGrowthYOY": "-0.851",
    "QuarterlyRevenueGrowthYOY": "-0.299",
    "AnalystTargetPrice": "128.26",
    "AnalystRatingStrongBuy": "3",
    "AnalystRatingBuy": "8",
    "AnalystRatingHold": "11",
    "AnalystRatingSell": "3",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "-",
    "ForwardPE": "32.47",
    "PriceToSalesRatioTTM": "6.59",
    "PriceToBookRatio": "2.842",
    "EVToRevenue": "5.22",
    "EVToEBITDA": "4.641",
    "Beta": "1.662",
    "52WeekHigh": "170.47",
    "52WeekLow": "62.55",
    "50DayMovingAverage": "131.38",
    "200DayMovingAverage": "105.61",
    "SharesOutstanding": "383240000",
    "DividendDate": "None",
    "ExDividendDate": "None"
}